One Za’abeel’s Coveted One&Only Private Homes and ‘The Residences’ Are Now Available for Sale, Announces Ithra Dubai
8.6.2022 07:30:00 EEST | Business Wire | Press release
Ithra Dubai, a leading real estate developer and asset manager, wholly owned by Investment Corporation of Dubai, announced the highly anticipated sale of One Za’abeel’s One&Only Private Homes and The Residences in Dubai’s most iconic address.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220529005001/en/
One Za’abeel, the multi-award-winning mixed-used development, is destined to become one of the UAE’s most recognizable architectural icons located right in Dubai’s business center. A marvel of engineering with the world’s longest cantilevered building, it is set to be awarded a GUINNESS WORLD RECORD™.
Suspended perpendicularly across the two towers at a height of around 100 meters and weighing 13,000 tonnes, The Link will host several engaging experiences and will include captivating entertainment venues, dining with celebrity chefs, an infinity pool, an observation deck with uninterrupted 360˚views of Dubai, and an immersive glass-floor experience.
One Za’abeel Tower offers 94 One&Only Private Homes for sale, the pinnacle of urban living in the world’s first vertical urban resort managed by the ultra-luxury One&Only brand. Located in some of the world’s most sought-after destinations, One&Only Private Homes offer upscale private residential sanctuaries with One Za’abeel being no exception. Reflecting the architecture, design, and lifestyle elements for which One&Only is celebrated, One&Only Private Homes offer unparalleled access to the luxury hospitality collection’s world-class resorts, in addition to a series of exclusive benefits.
One Za’abeel’s The Residences houses 264 apartments with a strategic location and lavish facilities. The residences for sale include 1, 2, 3, and 4-bedroom simplexes and duplexes and a 5-bedroom penthouse.
Available for lease in this mixed-use masterpiece is deluxe office space covering an area of 26,000 square and three floors of retail space, F&B, and leisure experiences at the Podium, covering an area of 12,000 square meters.
Strategically located in the heart of the city, at the intersection of Dubai’s famous Sheikh Zayed Road and its commercial business district, One Za’abeel is the gateway to Dubai International Financial District, close to Dubai World Trade Centre, Burj Khalifa, and Dubai International Airport.
“With its mesmerizing architecture, central location, and exceptional mix of offerings, One Za’abeel is an exceptional place to live, work, and spend leisure time in one of Dubai’s most desirable addresses, a true reflection of Dubai’s ambitious spirit,” said Issam Galadari, Director and CEO of Ithra Dubai.
In line with the UAE’s net-zero target for 2050, the development aims to achieve the highest standards of sustainability as it implements the Gold LEED certification requirements in its design and functionality.
About Ithra Dubai
Ithra Dubai LLC, wholly owned by Investment Corporation of Dubai (ICD), develops and manages a portfolio of pioneering real estate projects in Dubai and in key international markets. Its projects are designed to embrace diversity, shape happy communities, and bring prosperity to many. Ithra Dubai aims to deliver mixed-used developments on an ambitious scale, which incorporates world-class retail, commercial, residential, and leisure concepts.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005001/en/
Contact information
Yara Bou Hadir
pressenquiries@sabaconsultants.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom